# BeyondSpring, Inc. (BYSI) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/BYSI
## Company Profile
- Ticker: BYSI
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 0.789959 USD
- Market cap: 69903694 USD
- Last updated: 2026-08-11
## Business Overview
### Oncology Therapeutics Company
BeyondSpring develops first-in-class cancer therapies and supports a separately operated molecular glue degrader discovery platform through SEED Therapeutics.
### Plinabulin
Plinabulin is a late-stage asset studied across multiple cancers and is being positioned as a combination backbone that may improve both efficacy and tolerability of antibody-drug conjugate regimens.
### Combination Strategy
Preclinical work combines plinabulin with topoisomerase inhibitor ADCs and immune checkpoint inhibitors to address resistance and treatment-limiting toxicity.
### SEED Platform Exposure
SEED Therapeutics applies structure-based discovery to molecular glue degraders, giving BeyondSpring economic exposure to a separate targeted protein degradation pipeline.
## Why The Stock Is Moving

As of Aug 11, 2026, BYSI closed up 0.54% at $0.7900. No new same-company headline was identified in the current news window.

## Future Catalysts

- BeyondSpring’s catalysts are plinabulin and the company’s oncology / supportive-care programs, where the next update can either keep the story alive or push it further into the background. The stock is still sensitive to whether the clinical path stays credible.

## Recent News
- 2026-06-04 11:00 EST — [BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value](https://biopharmsignal.com/news/BYSI/beyondspring-announces-leadership-transition-to-deliver-focused-execution-on-its-7cdf7bc8) — Source: BeyondSpring, Inc.
- 2026-06-02 11:00 EST — [BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026](https://biopharmsignal.com/news/BYSI/beyondspring-presents-the-latest-update-of-a-phase-2-study-demonstrating-durable-b6c4b5ec) — Source: BeyondSpring, Inc.
- 2026-05-18 11:00 EST — [BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/BYSI/beyondspring-announces-poster-presentation-at-2026-asco-annual-meeting-121bfb8e) — Source: BeyondSpring, Inc.
- 2026-05-13 11:00 EST — [BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/BYSI/beyondspring-reports-first-quarter-2026-financial-results-and-provides-corporate-7bef7d23) — Source: BeyondSpring, Inc.
- 2026-04-22 11:00 EST — [BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs](https://biopharmsignal.com/news/BYSI/beyondspring-reports-compelling-new-data-plinabulin-advances-both-the-anticancer-ba2782eb) — Source: BeyondSpring, Inc.